Last updated: September 5, 2026
Ethinyl estradiol and segesterone acetate are commercialized in the U.S. as Annovera, a reusable vaginal contraceptive system developed by the Population Council and commercialized first by TherapeuticsMD and later by Mayne Pharma. The product received FDA approval in 2018 and introduced a 13-cycle, patient-controlled contraceptive ring that does not require monthly replacement by a health-care provider.
Annovera has a differentiated delivery system but a limited commercial base. Its market position depends on contraceptive access, insurance coverage, patient acceptance of vaginal delivery, physician education, and the ability to compete with low-cost oral contraceptives, long-acting reversible contraceptives, disposable vaginal rings, and over-the-counter options. Public disclosures indicate commercial growth after launch, but the product remains a relatively small branded asset compared with leading hormonal contraceptives.
What is Annovera and how does ethinyl estradiol/segesterone acetate work?
Annovera is a silicone vaginal system containing 103 mg of segesterone acetate and 17.4 mg of ethinyl estradiol. It releases approximately 0.15 mg of segesterone acetate and 0.013 mg of ethinyl estradiol daily when used according to the approved regimen.
The ring is inserted for 21 days and removed for seven days over 13 cycles. The same device is reused for one year. Segesterone acetate suppresses ovulation, while ethinyl estradiol supports cycle control and contributes to contraceptive efficacy. The product is indicated for females of reproductive potential to prevent pregnancy.
| Product characteristic |
Annovera |
| Active ingredients |
Segesterone acetate and ethinyl estradiol |
| Dosage form |
Reusable vaginal system |
| FDA approval |
August 2018 |
| Approved use |
Prevention of pregnancy |
| Use period |
One year, or 13 cycles |
| Administration |
Patient-controlled vaginal insertion and removal |
| Primary commercial sponsor |
Mayne Pharma |
| NDA |
209627 |
| Regulatory category |
Prescription hormonal contraceptive |
The product differs from NuvaRing and its generic equivalents because those products are generally replaced monthly. Annovera’s reusable design reduces the number of pharmacy transactions and eliminates the need for a new ring every cycle, although the upfront prescription price is higher than the monthly cost of many oral contraceptives.
What is the FDA regulatory status of ethinyl estradiol and segesterone acetate?
The FDA approved Annovera on August 10, 2018, under New Drug Application 209627. The FDA classified the product as a combined hormonal contraceptive and required labeling that addresses thromboembolic risk, smoking, hypertension, liver disease, breast cancer, and other contraindications associated with estrogen-containing contraceptives. [1]
The product received five-year new chemical entity exclusivity if the FDA determined that segesterone acetate qualified as a new active ingredient in the approved product. That regulatory exclusivity would have expired in 2023. Any remaining protection therefore depends primarily on listed patents, regulatory protections for the drug-device combination, and the technical difficulty of developing an equivalent reusable vaginal system.
FDA approval did not create a broad contraceptive monopoly for the active ingredients. Ethinyl estradiol is an established estrogen used in numerous products. Segesterone acetate is more differentiated, but commercial protection centers on the specific formulation, delivery system, dose, and use regimen.
What patents protect Annovera and when do they expire?
Annovera’s protection is based on patents covering the vaginal ring, hormone composition, drug release, and related product characteristics. Publicly available FDA Orange Book data and company disclosures should be reviewed together because patent listings and expiration dates can change through corrections, terminal disclaimers, pediatric extensions, or litigation outcomes.
The commercial patent estate is expected to extend beyond the five-year NCE exclusivity period and into the 2030s. The most important protection is the combination of segesterone acetate and ethinyl estradiol in a reusable vaginal system designed for extended use.
| Protection category |
Commercial relevance |
| Active-ingredient combination |
Covers the inclusion of segesterone acetate and ethinyl estradiol |
| Vaginal-ring composition |
Protects the silicone or polymeric delivery structure |
| Controlled release |
Limits substitutes using materially different release profiles |
| One-year reusable regimen |
Supports the 13-cycle use pattern |
| Drug-device combination |
Raises the development burden for an equivalent product |
| Method of contraception |
May cover use of the ring for pregnancy prevention |
The strongest barrier is likely the integrated drug-device design rather than ethinyl estradiol itself. A generic sponsor would need to establish pharmaceutical equivalence, bioequivalence or an FDA-accepted alternative standard, device performance, release characteristics, stability, and clinical or comparative evidence sufficient for approval.
When does Annovera lose exclusivity?
Annovera’s five-year NCE exclusivity period likely ended in 2023. That date permits certain ANDA activity if other regulatory and patent requirements are satisfied, but it does not necessarily permit commercial generic launch.
Commercial entry remains constrained by listed patents, any patent litigation, regulatory requirements for a reusable vaginal device, and the absence of an established FDA pathway for a direct generic equivalent. The practical loss-of-exclusivity date could therefore occur later than the NCE expiration date.
No publicly established, commercially launched generic equivalent had materially displaced Annovera through the latest broadly available company disclosures. The timing of generic entry depends on whether a challenger files a Paragraph IV certification, whether the patent holder sues within 45 days, and whether the challenger receives approval after litigation or settlement.
How strong is the Annovera patent estate?
The estate is moderately differentiated but not invulnerable.
Strengths include:
- A novel combination involving segesterone acetate.
- A reusable vaginal system with a one-year labeled use period.
- Drug-device integration that complicates conventional ANDA development.
- Limited direct competition using the same active ingredient and delivery architecture.
- Potential formulation and release-control claims that may be difficult to design around.
Weaknesses include:
- Ethinyl estradiol is widely used and commercially commoditized.
- Hormonal contraceptive delivery systems have substantial prior art.
- The product’s clinical and commercial value depends heavily on the ring rather than on an exclusive active pharmaceutical ingredient.
- A competitor could pursue a 505(b)(2) pathway or another hybrid regulatory strategy rather than a conventional ANDA.
- Method-of-use claims for contraception may be narrower than composition or device claims.
The patent estate is stronger against a direct copy than against a reformulated vaginal contraceptive using a different hormone, polymer, release mechanism, or duration of use.
What patent litigation and Paragraph IV risks affect Annovera?
Publicly available information has not established a major, market-disrupting Paragraph IV litigation campaign against Annovera comparable with litigation involving high-revenue small-molecule medicines.
The principal scenarios are:
- An ANDA sponsor files a Paragraph IV certification against listed patents.
- The sponsor receives approval after the 45-day litigation window expires without suit.
- The patent holder files an infringement action, triggering a potential 30-month stay.
- The parties settle under a license that permits a future generic launch.
- The FDA approves a competing product through a 505(b)(2) pathway or another regulatory route.
The litigation risk is asymmetric. A challenger must invest in a specialized drug-device program with uncertain market returns. The patent holder must show enough remaining commercial value to justify litigation and settlement costs. Annovera’s relatively modest revenue base reduces the economic incentive for an early challenge compared with a blockbuster medicine.
What is the commercial and competitive landscape for Annovera?
Annovera competes across several contraceptive categories rather than against one product.
| Competitive category |
Examples |
Competitive pressure |
| Oral contraceptives |
Generic ethinyl estradiol combinations, progestin-only pills |
Low price and broad availability |
| Monthly vaginal rings |
NuvaRing and generic equivalents |
Familiar vaginal route and monthly replacement |
| Long-acting reversible contraception |
Mirena, Liletta, Kyleena, Nexplanon |
High efficacy and lower adherence burden |
| Injectable contraception |
Depo-Provera and generics |
Infrequent administration |
| Transdermal systems |
Xulane and generics |
Non-oral delivery |
| Nonhormonal contraception |
Condoms, copper IUDs |
Different risk and preference profile |
| Over-the-counter products |
Opill and emergency contraception |
Expanded access and lower prescription friction |
Annovera’s core advantages are user control, one-year reuse, and reduced need for monthly pharmacy fulfillment. Its disadvantages include vaginal insertion, storage and cleaning requirements, contraindications associated with estrogen, a higher initial acquisition cost, and competition from highly effective implants and intrauterine systems.
The product is more likely to capture patients seeking a non-daily, non-IUD method than to convert the broad generic oral contraceptive market.
What drove Annovera’s financial trajectory?
TherapeuticsMD carried Annovera through the launch phase, but the company faced high selling, general and administrative expenses, limited commercial scale, and financial pressure across its women’s health portfolio. The company’s restructuring and asset transactions shifted commercial control to Mayne Pharma.
Mayne Pharma acquired U.S. commercial rights to Annovera and related women’s health assets from TherapeuticsMD in 2022. Public transaction reporting described consideration of up to approximately $140 million, consisting of upfront and contingent components tied to the acquired portfolio. [2]
The financial trajectory has four stages:
| Period |
Financial profile |
| 2018-2019 |
FDA approval and initial launch; limited market penetration |
| 2020-2021 |
Commercial disruption, pandemic-related access issues, and continued investment |
| 2022 |
Transfer of U.S. commercialization to Mayne Pharma |
| 2023 onward |
Focus on prescription growth, payer access, and portfolio-level profitability |
Public company filings indicate that Annovera generated increasing product revenue after launch, but neither the original sponsor nor Mayne has consistently disclosed a complete standalone income statement for the product. Gross sales, net sales, rebates, patient assistance, marketing costs, and manufacturing costs therefore cannot be treated as interchangeable measures.
The product’s financial leverage depends on scale. Manufacturing a reusable ring and supporting specialized distribution creates a relatively high fixed-cost base. Once prescriptions grow, the absence of a monthly replacement requirement may improve patient value but can reduce recurring unit volume compared with disposable monthly products.
What revenue exposure does Annovera create for Mayne Pharma?
Annovera is strategically important to Mayne Pharma’s women’s health portfolio but is not comparable in scale with the largest global contraceptive brands. Revenue exposure is concentrated in the United States because the product’s principal commercial infrastructure, FDA approval, and payer relationships are U.S.-focused.
Key financial variables include:
- Prescription volume and refill persistence.
- Gross-to-net deductions from rebates and discounts.
- Medicaid and commercial insurance coverage.
- Patient copay assistance.
- Direct-to-consumer advertising efficiency.
- Specialty pharmacy and retail distribution.
- Manufacturing yield and product returns.
- The pace of new contraceptive entrants.
- The timing of generic or hybrid competition.
A reasonable commercial interpretation is that Annovera can be a durable specialty women’s health product without becoming a mass-market contraceptive franchise. Its value is higher if Mayne expands payer coverage and reduces acquisition friction. Its value is lower if patients view the upfront price as excessive relative to generic pills or monthly rings.
What manufacturing and intellectual-property barriers limit generic entry?
A competing manufacturer must reproduce a complex product profile rather than simply match a tablet’s active ingredients. The development program may require:
- Controlled incorporation of two hormones into a vaginal ring.
- Consistent daily release over 21-day use periods.
- Stability during storage and repeated insertion and removal.
- Maintenance of dose delivery over 13 cycles.
- Demonstration of device integrity and acceptable mechanical performance.
- Packaging and storage controls.
- Human factors and patient-use evaluation.
- Regulatory studies addressing pharmacokinetics and safety.
These requirements increase development costs and may reduce the number of potential challengers. A competitor could instead develop a different vaginal contraceptive system, but such a product would face its own clinical, regulatory, and commercial hurdles.
How does Annovera compare with NuvaRing and long-acting contraceptives?
| Attribute |
Annovera |
Generic NuvaRing |
IUD or implant |
| Replacement interval |
Annual device |
Monthly |
Several years |
| Patient-controlled |
Yes |
Yes |
Usually clinician insertion |
| Estrogen exposure |
Yes |
Usually yes |
Varies by product |
| Reusable |
Yes |
Generally no |
No |
| Upfront price |
Relatively high |
Lower per cycle |
High procedure-related cost |
| Adherence burden |
Monthly insertion/removal schedule |
Monthly replacement |
Low after insertion |
| Primary differentiation |
Reusable one-year ring |
Familiar monthly ring |
Long duration and efficacy |
Annovera’s commercial position is strongest among patients who want control over initiation and discontinuation but do not want a daily pill or an intrauterine device. Its position is weaker against generic monthly rings when price is the primary decision factor.
What generic launch scenarios exist for Annovera?
Three scenarios are commercially plausible.
Delayed direct generic entry
A challenger waits until key patents expire or reaches a settlement permitting launch. This outcome protects Mayne’s near-term revenue but creates a later price-driven decline.
Authorized or licensed competition
The patent holder licenses a manufacturer to launch after a negotiated date. This can preserve some value through royalties while expanding access and reducing litigation risk.
Non-infringing alternative vaginal ring
A competitor develops a different formulation, dose, polymer, or delivery schedule. This route avoids direct copying but requires a separate clinical and regulatory investment and may not be substitutable for Annovera.
The highest-risk event for Mayne would be an FDA-approved direct substitute with broad payer coverage and a materially lower net price. The risk is lower if competing products require a different approval pathway or fail to match Annovera’s one-year use profile.
Key Takeaways
- Annovera is the only widely commercialized one-year reusable vaginal contraceptive system based on ethinyl estradiol and segesterone acetate.
- FDA approval occurred in 2018 under NDA 209627.
- Five-year NCE exclusivity likely ended in 2023, but patent and device-related barriers can extend effective market protection.
- The product’s commercial differentiation comes from its reusable ring and 13-cycle regimen, not from ethinyl estradiol.
- Mayne Pharma acquired U.S. commercial rights after TherapeuticsMD experienced financial and strategic pressure.
- Annovera has growth potential in patient-controlled contraception but competes against inexpensive generics and highly effective long-acting methods.
- Public disclosures do not establish a major generic launch or a market-changing Paragraph IV litigation outcome.
- Revenue growth depends on payer access, prescription persistence, net pricing, and lower customer-acquisition costs.
- Generic risk is more likely to emerge through a specialized drug-device challenge or a non-infringing vaginal-ring alternative than through a simple tablet-style generic.
FAQs
Is Annovera the same as NuvaRing?
No. Both are vaginal hormonal contraceptives, but Annovera is reusable for one year, while NuvaRing and its generic equivalents are generally replaced monthly. The active ingredients and release systems also differ.
Is segesterone acetate available in other FDA-approved drugs?
Segesterone acetate is principally associated with Annovera in the U.S. Its limited commercial use supports product differentiation but does not create permanent exclusivity.
Can a generic company copy Annovera after 2023?
The end of NCE exclusivity does not automatically permit launch. A generic sponsor must address listed patents, FDA requirements for the drug-device combination, and any litigation or settlement restrictions.
Is Annovera covered by insurance?
Coverage varies by commercial plan, Medicaid program, formulary status, and state contraceptive-access rules. Net revenue depends heavily on rebates, copay support, and reimbursement conditions rather than on the published list price alone.
What is the main investment risk for Annovera?
The main risks are slower prescription growth, inadequate payer coverage, high marketing costs, competition from low-cost generic contraceptives, and eventual entry by a direct or alternative vaginal-ring competitor.
References
- U.S. Food and Drug Administration. (2018). FDA approves new vaginal ring for birth control that can be used for one year. https://www.fda.gov
- Mayne Pharma. (2022). Mayne Pharma completes acquisition of U.S. women’s health assets from TherapeuticsMD. Mayne Pharma investor materials.
- U.S. Food and Drug Administration. (2024). Annovera prescribing information. https://www.accessdata.fda.gov
- Mayne Pharma. (2023). Annual report and investor disclosures. Mayne Pharma Limited.
- TherapeuticsMD. (2022). Filings and disclosures concerning the sale of women’s health assets. U.S. Securities and Exchange Commission.
